Sumant Rajendran heads up the Marketing department and brings over 20 years’ experience to Scilex. He has been at the company since mid-2019 and has overseen the growth of our marketed portfolio from one product (ZTlido) to three (with the addition of Elyxyb and Gloperba). Besides this, Sumant is closely involved in advancing our clinical portfolio in a rational manner to set our pipeline products up for commercial success.
Sumant is the architect of the novel ZTlido campaign (“the perfect partner to gabapentinoids”) that has helped spark rapid brand growth from 2023, and of the impending Gloperba launch campaign (“precision, lowered dosing of colchicine”).
His industry experience spans both biologics and small molecules, at companies large (Amgen), mid-sized (Eisai) and small (Depomed); and therapeutic areas including Pain, Oncology, Metabolic Disease, Rheumatology and Dermatology. He has worked on best-in-class products such as Enbrel (etanercept) and Aloxi (palonosetron), as well as lead and grown multiple specialty products, including Pain brands such as Gralise (once daily gabapentin) and Zipsor (diclofenac potassium).
Sumant was selected and recognized by PM360 magazine in 2021 as an “Elite Strategist” in the pharmaceutical industry. Sumant holds an MBA from the University of Southern California, an MS from the University of the Ryukyus, Okinawa, Japan and BS from Loyola College, Chennai, India.